The Company may be the first to offer an all-natural 'cancer cocktail combining the therapeutic benefits of the plant and animal kingdoms - HANCOCK, Maryland, - (http://www.financialnewsmedia.com
News Alert) - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually.
PetLife's new patent-pending formulation has created a 'cancer cocktail' combining both Blue Scorpion Venom Chlorotoxin with plant-based phytonutrients. Preliminary testing has shown inhibition against certain cancer cell line studies without toxicity. Across the world, researchers have recognized that many cells which cause disease, have the ability to become resistant to treatment when only one drug is used. Combination therapy is increasing, recommended for the treatment of both neoplastic (cancer) and infectious disease. The 'HIV Cocktail', which changed the world's approach to the treatment of HIV, is a similar approach comparison. PetLife's new 'cancer cocktail' may prove to be the non-toxic alternative to the harmful and sometimes deadly side effects of radiation and chemotherapy. The patent pending formulation of PetLife's new 'cancer cocktail' has the curious ability to bind selectively to cancer cells and inhibit their growth demonstrating little to no side effects to the patient. Read this and more news for PetLife at http://www.financialnewsmedia.com/profiles/ptlf.html
For hundreds, if not thousands of years, plant-based medicinals have formed the foundation of therapeutic treatment in the Chinese, Native American and Ayurvedic traditions. More recently, scientists have discovered the mode of action of many of these therapies. In many cases, the chemical compounds have been manipulated or synthesized to create new chemical entitles ("NCE"). Along with the creation of NCEs comes the inherent risk of unintended consequences and adverse reactions. By maintaining an all-natural formulation, PetLife intends to capture the therapeutic benefit of plant-based therapy without the creation of any unintended consequences. Our team has identified certain phytonutrients which can work synergistically with Blue Scorpion Venom for inhibition of cancer cell growth.
"Our new formulation, RX002CxN, will become the basis of PetLife Pharmaceutical's new product portfolio, Vitalzul[TM], a novel treatment option for the treatment of cancer and potentially other indications. The low toxicity of our formulation gives additional benefit. Given the comparative biology of animals and humans, it is our hope that success in treatment of cancer in animals will lead to similar results in humans. Our new formulation has been designed with both human and animal applications in mind. Once testing is completed, the Company will strategically determine the best course of development in both the pet and human markets," stated Dr. Vivekananda Ramana, Chief Medical Officer of the Company.
"This groundbreaking, patent pending biotechnology will serve as the core ingredient in our pharma product Vitalzul[TM] once we complete the much anticipated FDA trials. It is well known that animal research and studies are the foundation of human applications. Our first goal is to complete the successful testing, FDA application and commercialization for the benefit of animals. Then, we will move aggressively in expanding our research in the human arena, where we anticipate strong interest from industry leaders," added Dr. Salvagno.
About PetLife Pharmaceutical
PetLife Pharmaceuticals, Inc. (PTLF) (http://www.PetLifePharma.com
) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, Vitalzul[TM], is currently in testing. Vitalzul[TM]'s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets will launch in 2017. PetLife Scorpion Ranch™ will break ground in 2017. PetLife anticipates incorporating Vitalzul[TM] in a new and advanced therapeutic pet food line in 2019.
Forward looking statement:
This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
+1-844-473-8543 ext. 701
SOURCE Petlife Pharmaceuticals, Inc.
Disclaimer: FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated four thousand two hundred dollars for PetLife Pharmaceuticals, Inc. coverage by the company. FNMG HOLDS NO SHARES OF PetLife Pharmaceuticals, Inc.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.